Phaseline

Targets › DAO

DAO (D-amino-acid oxidase): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 2; Neurology, Infectious disease; next expected readout May 2027.

Catalyzes the oxidative deamination of D-amino acids with broad substrate specificity. Required to catabolize D-amino acids synthesized endogenously, of gastrointestinal bacterial origin or obtained from the diet, and to use these as nutrients (By similarity). (UniProt, P14920)

Open in Phaseline: the race on DAO, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chang Gung Memorial HospitalDAOIB plus AO
NMDA-enhancing agent (DAO inhibitor) plus antioxidant
DAOPhase 2Dementia; Alzheimer Disease; Long COVIDMay 2027

Conditions

Dementia (1) Alzheimer Disease (1) Long COVID (1)

Modalities

small molecule (1)

Companies

Chang Gung Memorial Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.